Agilent Technologies, Inc. (A) Price Target Cut to $155 at Baird

FierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target

FierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer

FierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapy

FierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia

FierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reports

Lonza NewsSimulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus

Lonza NewsSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com

Lonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com

BioWorldJapanese researchers report new μ-opioid receptor antagonists

BioWorldIncyte discloses new TYK2 and/or JAK1 inhibitors

BioWorldInsilico Medicine divulges new NLRP3 inflammasome inhibitors

BioWorldNeolaia synthesizes new CD38 inhibitors